消息方面，药明康德近日宣布，公司在2024年标普全球企业可持续发展评估(S&P Global Corporate Sustainability Assessment, CSA)中获得行业最高分，位列全球"生命科学工具与服务"领域第一。① What are the measures to support the field of innovative medicines at the policy level? ② What adverse effects might Trump's election have on domestic pharmaceutical stocks?
Financial Services Association, November 12 (Editor: Hu Jiarong) Driven by recent positive developments, most Hong Kong pharmaceutical stocks have strengthened today. As of press release, Gloria Ying (06821.HK), Pharmaceutical Kangde (02359.HK), Kanglong Chemical (03759.HK), and Zhaoyan New Pharmaceutical (06127.HK) were up 3.65%, 3.36%, 3.11%, and 2.72% respectively.
Note: Performance of pharmaceutical stocks
In terms of news, Yao Ming Kangde recently announced that the company received the highest score in the industry in the 2024 S&P Global Corporate Sustainability Assessment (CSA), ranking first in the global “life science tools and services” field.
According to public information, CSA is the world's leading corporate sustainability assessment tool, which quantifies the disclosure of information and performance of companies in the industry on economic, environmental and social standards. As a third-party independent and credible benchmark for the industry, CSA links an enterprise's sustainability performance to its business strategy, and fully reflects the company's sustainability management level.
Furthermore, the policy level shows the country's support for the field of innovative drugs. For example, the “Report on the Work of the Government” mentions innovative drugs, and the review and approval of the “Full Chain Implementation Plan to Support the Development of Innovative Drugs”. Among them, policies in Beijing, Guangzhou, and Zhuhai also support increasing the speed of admission of innovative drugs and lowering the sales threshold.
Agencies say Trump's election may be bad for domestic pharmaceutical stocks
According to SPDB International's report, after Trump's election, the probability that the Biosafety Act will be enacted separately may rise, and the overseas interest rate cut process may slow down, which may lead to a decline in market sentiment in the CXO industry.
Previously, H.R. 8333 was voted by the House of Representatives in September. It was mainly promoted by the Republican Party, and the vast majority of opposition votes came from the Democratic Party. After Trump comes to power, it may cause the Federal Reserve's interest rate cut process to slow down, which will affect the recovery of overseas biomedical financing, as well as the CXO industry's short-term rate of new overseas orders and the order conversion revenue cycle.
